These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28406524)

  • 1. Androgen receptor-positive, triple-negative breast cancer.
    Gucalp A; Traina TA
    Cancer; 2017 May; 123(10):1686-1688. PubMed ID: 28406524
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the androgen receptor in triple-negative breast cancer.
    Gucalp A; Traina TA
    Curr Probl Cancer; 2016; 40(2-4):141-150. PubMed ID: 27816190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.
    Gerratana L; Basile D; Buono G; De Placido S; Giuliano M; Minichillo S; Coinu A; Martorana F; De Santo I; Del Mastro L; De Laurentiis M; Puglisi F; Arpino G
    Cancer Treat Rev; 2018 Jul; 68():102-110. PubMed ID: 29940524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Androgen receptors in breast cancer: Expression, value and therapeutic prospects].
    Héquet D; Mzoughi S; Rouzier R; Guccione E
    Bull Cancer; 2017 Apr; 104(4):363-369. PubMed ID: 28216075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?
    Anestis A; Karamouzis MV; Dalagiorgou G; Papavassiliou AG
    Cancer Treat Rev; 2015 Jun; 41(6):547-53. PubMed ID: 25944485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Androgen receptor-positive triple negative breast cancer: From biology to therapy].
    Grellety T
    Bull Cancer; 2020 Apr; 107(4):506-516. PubMed ID: 32145961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer.
    Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA
    Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer: molecular subtypes and targeted therapy.
    Hirshfield KM; Ganesan S
    Curr Opin Obstet Gynecol; 2014 Feb; 26(1):34-40. PubMed ID: 24346128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data.
    Rhanine Y; Bonnefoi H; Goncalves A; Debled M; Le Moulec S; Bonichon N; Macgrogan G; Arnedos M; Dubroca-Dehez B; Grellety T
    Breast; 2024 Feb; 73():103667. PubMed ID: 38160476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative breast cancer: not entirely negative.
    Leone JP; Puhalla S
    Oncology (Williston Park); 2013 Sep; 27(9):856, 858-9. PubMed ID: 24282979
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
    Jia LY; Shanmugam MK; Sethi G; Bishayee A
    Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancer in the post-genomic era.
    Williams N; Harris L
    Oncology (Williston Park); 2013 Sep; 27(9):859-60, 864. PubMed ID: 24282980
    [No Abstract]   [Full Text] [Related]  

  • 16. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
    Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
    J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
    [No Abstract]   [Full Text] [Related]  

  • 17. New targets for triple-negative breast cancer.
    Herold CI; Anders CK
    Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibitors in breast cancer: hype or promise?
    McArthur HL
    Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806
    [No Abstract]   [Full Text] [Related]  

  • 19. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What common biomarkers characterize a triple-negative profile in breast cancer?
    Kallel I; Rebaï M; Khabir A; Rebaï A
    Pathol Biol (Paris); 2015 Sep; 63(4-5):224-9. PubMed ID: 26300241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.